ImmunoCellular Therapeutics, Ltd. (IMUC) - NYSEMKT
  • Tue, Jun. 7, 7:07 AM
    • The first patient has been treated in ImmunoCellular Therapeutics' (NYSEMKT:IMUC) Phase 3 clinical trial evaluating lead product candidate ICT-107 in patients with newly diagnosed glioblastoma, the most common and most aggressive type of brain tumor.
    • The randomized, double-blind, placebo-controlled study will enroll 414 HLA-A2-positive subjects across 120 sites in the U.S., Canada and the EU. The primary endpoint is overall survival. According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint is December 2019. The estimated study completion date is December 2021.
    • ICT-107 is an autologous dendritic cell immunotherapeutic that targets six different antigens associated with glioblastoma. It is designed for use following surgical tumor resection of newly diagnosed glioblastoma in combination with radiotherapy and chemotherapy.
    | Tue, Jun. 7, 7:07 AM | 1 Comment
  • Thu, May 12, 4:22 PM
    • ImmunoCellular Therapeutics (NYSEMKT:IMUC): Q1 EPS of -$0.06 beats by $0.01.
    • Press Release
    | Thu, May 12, 4:22 PM
  • Thu, Mar. 31, 6:59 AM
    • ImmunoCellular Therapeutics (IMUC) FY15 results: Revenues: $0; R&D Expense: $10.9M (+81.7%); SG&A: $4.6M (+17.9%); Operating Loss: ($15.5M) (-56.6%); Net Loss: ($12.8M) (-36.2%); Loss Per Share: ($0.15) (+6.3%); Quick Assets: $22.6M (-2.6%).
    • No guidance given.
    | Thu, Mar. 31, 6:59 AM
  • Wed, Mar. 30, 4:20 PM
    • ImmunoCellular Therapeutics (NYSEMKT:IMUC): FY'15  EPS of -$0.15 in-line.
    • Press Release
    | Wed, Mar. 30, 4:20 PM
  • Dec. 1, 2015, 7:31 AM
    • ImmunoCellular Therapeutics (NYSEMKT:IMUC) inks an agreement with the European Organisation for Research and Treatment of Cancer (EORTC) for the Phase 3 clinical trial assessing lead product candidate ICT-107 in patients with newly diagnosed glioblastoma. The EORTC contributed to the design of the trial and will assist the company in accruing patients for the study in Europe.
    • EORTC Brain Tumor Group Chair Professor Michael Weller says, "The EORTC is a leader in enabling multi-disciplinary approaches to investigate strategic therapeutic questions through clinical and translational research. We aim to improve the understanding of disease and help advance innovative therapies in cancer care for the benefit of patients. We are pleased to collaborate with ImmunoCellular to conduct the Phase 3 registration trial of ICT-107, a potentially promising cancer immunotherapeutic approach to treating brain cancer."
    • The Phase 3 study should commence in the next few weeks.
    • ICT-107 is an autologous dendritic cell immunotherapeutic that targets six different antigens associated with glioblastoma, the most common and lethal form of brain cancer. It is designed for use following surgical tumor resection of newly diagnosed glioblastoma in combination with radiotherapy and chemotherapy.
    | Dec. 1, 2015, 7:31 AM
  • Nov. 20, 2015, 12:17 PM
    • Nano cap ImmunoCellular Therapeutics (IMUC -13.3%) slumps on triple normal volume in response to its announcement of results from a mid-stage study of lead product candidate ICT-107 in patients with brain cancer (glioblastoma). The data are being presented at the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology in San Antonio, TX.
    • In the 124-patient intent-to-treat population, median overall survival (OS) in patients receiving ICT-107 was only 10% better than placebo and fell short of statistical significance.
    • In a pre-specified subgroup, those seropositive for HLA-A2 (human leukocyte antigen alpha 2), which helps the immune system detect and attack cancer cells, the positive effect from ICT-107 was more profound. In a group categorized as MGMT methylated, those receiving ICT-107 experienced median OS of 13.8 months or 58% better than placebo. In MGMT unmethylated subjects, median OS was 4.0 months or 34% better than placebo. MGMT methylation is associated with improved response to radiation and chemotherapy. Neither difference achieved statistical significance, though, because they were not powered to do so.
    • In HLA-A2+ patients, 60% of those in the ICT-107 cohort showed a statistically significant immune response versus 36% for placebo (an immune response is associated with survival). In addition, those treated with ICT-107 experienced a statistically valid survival benefit (p=0.0084). Immune response was similar in the MGMT methylated and unmethylated groups.
    • Based on these data, the company's Phase 3 design will target HLA-A2+ patients, both MGMT methylated and unmethylated. The randomized, double-blind, 400-subject, placebo-controlled trial will commence shortly. The primary endpoint will be OS. According to clinicaltrials.gov, the estimated final data collection date for the primary endpoint is December 2019. The estimated study completion date is December 2021.
    | Nov. 20, 2015, 12:17 PM | 16 Comments
  • Nov. 11, 2015, 8:18 AM
    • ImmunoCellular Therapeutics (IMUC -4.7%) Q3 results: Revenues: $0; R&D Expense: $2.6M (+73.3%); SG&A: $0.9M (+12.5%); Operating Loss: ($3.7M) (-54.2%); Net Loss: ($3.4M) (-78.9%); Loss Per Share: ($0.04) (-33.3%); Quick Assets: $24.4M (+5.2%).
    • No guidance given.
    | Nov. 11, 2015, 8:18 AM
  • Nov. 10, 2015, 4:18 PM
    • ImmunoCellular Therapeutics (NYSEMKT:IMUC): Q3 EPS of -$0.04 beats by $0.02.
    | Nov. 10, 2015, 4:18 PM
  • Sep. 24, 2015, 3:33 PM
    • California's stem cell agency, California Institute for Regenerative Medicine, awards ImmunoCellular Therapeutics (IMUC +19.5%) $19.9M to support the Phase 3 clinical trial of ICT-107 in patients with newly diagnosed glioblastoma. The funds were granted under the Institute's CIRM 2.0 program, a comprehensive collaborative initiative designed to accelerate the development of stem cell-based treatments for people with unmet medical needs. ICT-107 qualified for consideration on the basis of being specifically engineered as an immunotherapy that selectively targets and kills tumor stem cells with the goal of preventing tumor recurrence following standard-of-care treatment.
    • The funds will be dispersed over the duration of the study, expected to commence in Q4. The estimated final data collection for the primary endpoint (overall survival at 46 months vs. placebo) is December 2019. The estimated study completion date is December 2021.
    • ICT-107 is an autologous dendritic cell immunotherapeutic that targets six different antigens associated with glioblastoma, the most common and lethal form of brain cancer. It is designed for use following surgical tumor resection of newly diagnosed glioblastoma in combination with radiotherapy and chemotherapy.
    | Sep. 24, 2015, 3:33 PM | 3 Comments
  • Aug. 13, 2015, 8:16 AM
    • The FDA approves the Special Protocol Assessment (SPA) for ImmunoCellular Therapeutics' (NYSEMKT:IMUC) Phase 3 clinical trial evaluating its lead product candidate, Orphan Drug-tagged ICT-107, in patients newly diagnosed with glioblastoma. The randomized, double-blind, placebo-controlled study will enroll ~400 HLA-A2-positive (specific class of patients that have previously responded well to ICT-107 treatment) subjects across ~120 sites in the U.S., Canada and European Union. The primary endpoint is overall survival. Secondary endpoints include progression-free survival and overall survival in two pre-specified MGMT subgroups. Enrollment will commence no later than Q4.
    • ICT-107 is an autologous dendritic cell immunotherapeutic that targets six different antigens associated with glioblastoma, the most common and lethal form of brain cancer. It is designed for use following surgical tumor resection of newly diagnosed glioblastoma in combination with radiotherapy and chemotherapy.
    | Aug. 13, 2015, 8:16 AM | 4 Comments
  • Aug. 6, 2015, 4:04 PM
    • ImmunoCellular Therapeutics (NYSEMKT:IMUC): Q2 EPS of -$0.03 beats by $0.02.
    | Aug. 6, 2015, 4:04 PM
  • May 19, 2015, 6:32 PM
    • Immunocellular Therapeutics (NYSEMKT:IMUC) amends its exclusive license agreement with Cedars-Sinai Medical Center that it originally consummated in November 2006. Under the amended agreement, the company acquires certain intellectual property and technology related to cellular therapies for the treatment of brain tumors, other cancers and neurodegenerative diseases. It will also have the exclusive rights to develop, use, manufacture, sell and grant sublicenses to the licensed technology.
    • IMUC will pay Cedars-Sinai milestone payments related to the development and commercialization of ICT-107, ICT-121 and ICT-140, specifically when it initiates patient enrollment in the first Phase 3 study for the firm's first product and upon the first commercial sale of the first product. If both milestones are achieved, the payment will be $1.1M. Cedars-Sinai will also be eligible to receive single-digit percentages of gross revenues from product sales and high-single digit to low-double digit percentages of IMUC's sublicense income.
    • Shares are down a fraction after hours on light volume.
    | May 19, 2015, 6:32 PM | 2 Comments
  • May 12, 2015, 9:33 AM
    • ImmunoCellular Therapeutics (IMUC -0.3%) Q1 results: Revenues: $0; R&D Expense: $2M (+17.6%); SG&A: $0.9M (+3.4%); Operating ($3.1M) (-14.8%); Net Loss: ($1.4M) (+56.3%); Loss Per Share: ($0.02) (+60.0%); Quick Assets: $34.8M (+50.0%).
    • No guidance given.
    | May 12, 2015, 9:33 AM
  • May 11, 2015, 4:07 PM
    • ImmunoCellular Therapeutics (NYSEMKT:IMUC): Q1 EPS of -$0.02 beats by $0.01.
    | May 11, 2015, 4:07 PM
  • Mar. 10, 2015, 7:54 AM
    • ImmunoCellular Therapeutics (IMUC -6.8%) FY14 results: Revenues: $0; R&D Expense: $6M (+13.2%); SG&A: $3.2M (-5.9%); Opearting Loss: ($9.9M) (-4.2%); Net Loss: ($9.4M) (-6.8%); Loss Per Share: ($0.16) (unch); Quick Assets: $23.2M (-15.9%).
    • No guidance given.
    | Mar. 10, 2015, 7:54 AM
  • Mar. 9, 2015, 4:04 PM
    • ImmunoCellular Therapeutics (NYSEMKT:IMUC): Q4 EPS of -$0.03 beats by $0.02.
    | Mar. 9, 2015, 4:04 PM
Company Description
ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States